Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer

Fineline Cube Feb 25, 2026
Company Deals

MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks

Fineline Cube Feb 25, 2026
Company Deals

Junshi Biosciences Partners with Antengene on Cancer Combination – JS207 PD‑1/VEGF Bispecific Plus ATG‑037 CD73 Inhibitor

Fineline Cube Feb 25, 2026
Company Deals

Dartsbio Licenses PACAP Antibody DS009 to Slate Medicines – $130M Series A Fuels Global Migraine Development

Fineline Cube Feb 25, 2026
Company Deals

Henlius Licenses Serplulimab to Abbott for Emerging Markets – Expands Anti‑PD‑1 Global Footprint

Fineline Cube Feb 25, 2026
Policy / Regulatory

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Fineline Cube Feb 24, 2026
Company Drug

United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential

Fineline Cube Feb 25, 2026
Company Drug

Bio-Thera’s BAT4406F BLA Accepted by NMPA – Next‑Gen Anti‑CD20 mAb for Rare Disease NMOSD

Fineline Cube Feb 25, 2026
Company Drug

Phanes Therapeutics’ PT886 Receives CDE Approval for Clinical Trials in Advanced Solid Tumors

Fineline Cube Feb 20, 2024

Sino-US biotechnology company Phanes Therapeutics Inc. has announced that it has received clinical trial approval...

Company Drug

ImmunoTech Biopharm Gets NMPA Green Light for Clinical Study of aT19 Injection for B-ALL

Fineline Cube Feb 20, 2024

ImmunoTech Biopharm Ltd (HKG: 6978), a specialist in chimeric antigen receptor T-cell (CAR-T) therapies based...

Policy / Regulatory

Beijing, Tianjin, and Hebei Release Draft Proposal for Updated Drug Clinical Trial Inspection Standards

Fineline Cube Feb 20, 2024

The medical products administration bureaus of Beijing, Tianjin, and Hebei province have released a draft...

Company Drug

AstraZeneca’s Tagrisso Wins Expanded FDA Approval for EGFR-mutated NSCLC

Fineline Cube Feb 20, 2024

UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has received a new indication approval from the...

Company Drug

Innovent Biologics’ IBI311 Achieves Primary Endpoint in Phase III Study for Thyroid Eye Disease

Fineline Cube Feb 20, 2024

Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, has announced that its...

Policy / Regulatory

China’s CDE Issues Guiding Principles for ADC Research and Evaluation

Fineline Cube Feb 20, 2024

China’s Center for Drug Evaluation (CDE) has issued a notification outlining the “Guiding Principles for...

Company Legal / IP Policy / Regulatory

GSK and Peers Respond to FTC Criticism, Withdraw Patent Listings from US Orange Book

Fineline Cube Feb 20, 2024

Three pharmaceutical companies, including the UK’s GSK (NYSE: GSK), have responded to the Federal Trade...

Company Deals

Astellas Pharma Partners with Kelonia Therapeutics to Advance CAR-T Cell Therapies

Fineline Cube Feb 19, 2024

Astellas Pharma Inc. (TYO: 4503) has announced a strategic research collaboration and licensing agreement with...

Company Drug

Denali Therapeutics Faces Setback as ALS Trial Fails to Meet Primary Endpoint

Fineline Cube Feb 19, 2024

Denali Therapeutics (NASDAQ: DNLI) has announced disappointing results from a Phase II trial of its...

Policy / Regulatory

China’s NMPA Releases 77th Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Feb 19, 2024

The National Medical Products Administration (NMPA) has released the 77th batch of reference drugs for...

Policy / Regulatory

GSK’s Avodart Receives NMPA Approval to Resume Sales in China from September

Fineline Cube Feb 19, 2024

The National Medical Products Administration (NMPA) has released a notification announcing that GlaxoSmithKline’s (GSK) Avodart...

Policy / Regulatory

National Health Commission Notification Signals New Poliovirus Containment Measures

Fineline Cube Feb 19, 2024

The National Health Commission (NHC) has issued a notification announcing the establishment of the National...

Policy / Regulatory

China’s NHC Approves 2023 Large Medical Equipment Configuration Licenses, Targets Cancer Treatment

Fineline Cube Feb 19, 2024

The National Health Commission (NHC) has granted approval for the Class A large medical equipment...

Company Drug

Hainan Poly Pharm Wins FDA Nod for Generic Version of UCB’s Vimpat

Fineline Cube Feb 19, 2024

Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it...

Company Policy / Regulatory

US Lawmakers Call for Sanctions Against WuXi AppTec and WuXi Biologics Over National Security Concerns

Fineline Cube Feb 19, 2024

US politicians have intensified their opposition to China’s biotech industry, with Congressmen and Senators sending...

Company

Novartis Begins Review of 70% Stake in Indian Unit, Strategic Options Under Consideration

Fineline Cube Feb 18, 2024

Novartis (NYSE: NVS) has initiated a review process concerning its 70.68% stake in Novartis India...

Company Medical Device

Boao Yiling Life Care Center Launches Innovative Dental Technologies Under Pilot Medical Policy

Fineline Cube Feb 18, 2024

Boao Yiling Life Care Center has successfully completed the inaugural use of a dental comprehensive...

Company Deals

Brii Biosciences Acquires VBI Vaccines’ Intellectual Property and Manufacturing Rights in Strategic Deal

Fineline Cube Feb 18, 2024

Brii Biosciences Ltd (HKG: 2137), based in China, has reached an agreement with US-based VBI...

Company

LianBio to Wind Down Operations Amid Market Challenges, Announces Special Dividend

Fineline Cube Feb 18, 2024

LianBio (OTCMKTS: LIANY), one of China’s prominent biotechnology firms, has announced plans to wind down...

Policy / Regulatory

NMPA Launches Pilot Program to Streamline Supplementary Drug Approval Process

Fineline Cube Feb 18, 2024

The National Medical Products Administration (NMPA) has unveiled the “Pilot Work Plan for Optimizing the...

Posts pagination

1 … 361 362 363 … 626

Recent updates

  • United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential
  • Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer
  • Bio-Thera’s BAT4406F BLA Accepted by NMPA – Next‑Gen Anti‑CD20 mAb for Rare Disease NMOSD
  • MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks
  • Junshi Biosciences Partners with Antengene on Cancer Combination – JS207 PD‑1/VEGF Bispecific Plus ATG‑037 CD73 Inhibitor
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential

Company Deals

Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer

Company Drug

Bio-Thera’s BAT4406F BLA Accepted by NMPA – Next‑Gen Anti‑CD20 mAb for Rare Disease NMOSD

Company Deals

MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.